Is K-Swiss OK?

Recs

2

Domestic firms with international operations have best been able to withstand rising home foreclosures and other inflationary trends that are putting a serious dent in personal pocketbooks. Footwear firm K-Swiss (Nasdaq: KSWS) is fortunate enough that 60% of first-quarter sales stemmed from overseas, but for reasons I'll get to below, that may not be enough to keep it on solid footing.

International sales grew a modest 2.1% for the quarter but didn't prove sufficient in offsetting a 33.6% plummet in domestic sales, which sent the overall top line down 16% to $102.9 million and earnings down by more than half to $0.20. The difficulties here at home are no surprise to those who have been following K-Swiss for a while now, but the global trends look to be petering out. In the words of the company's president: "Based on initial indications in our futures orders, the long-term momentum we have enjoyed internationally appears to be coming to an end." As with footwear and apparel behemoth Nike (NYSE: NKE), futures orders allow investors to peer slightly into the future on the sales front. Unfortunately for K-Swiss, domestic futures orders for shipment dates between April and September this year are tracking down a whopping 46.8% domestically and down a more modest 2.8% internationally.

Challenges on the sales front caused management to update guidance: It now expects full-year sales of $305 million-$330 million and earnings of just $0.05-$0.25. That's admittedly quite a big range and leaves enough wiggle room to come close to what the market is expecting -- if it hits the high end of its targets. But as it stands currently, profit trends at K-Swiss are wearing thin and at risk of falling into the red for 2008.

This is in stark contrast to rivals such as Nike, Wolverine World Wide (NYSE: WWW), and Skechers (NYSE: SKX), each of which are taking advantage of geographic depth to weather a touchy U.S. climate. For now, K-Swiss will have to try and survive with two left feet, much like Crocs (Nasdaq: CROX) and Heelys (Nasdaq: HLYS), which are also tripping around in most aspects of their businesses.

Related Foolishness:

“Make Big Money With Options” Motley Fool CFO Ollen Douglass recently made over $100,000 buying options on 7 well known stocks. Now we’re committed to turning his small fortune into a massive one! And we want you to join us! Enter your email address to hear more:

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 632820, ~/Articles/ArticleHandler.aspx, 12/1/2009 11:08:04 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
The Public Health-Care Plan's Problem

Related Tickers

12/1/2009 10:46 AM
NKE $64.97 Up +0.08 +0.12%
Nike, Inc. CAPS Rating: ****
SKX $22.33 Up +0.25 +1.13%
SKECHERS USA INC CAPS Rating: ***
WWW $25.97 Up +0.40 +1.56%
Wolverine World Wi… CAPS Rating: ****
CROX $5.00 Up +0.13 +2.67%
Crocs, Inc. CAPS Rating: *
KSWS $8.85 Up +0.12 +1.37%
K-Swiss, Inc. CAPS Rating: ***

Community: Investing Wiki

Term Of The Hour

PDUFA: The Prescription Drug User Fee Act (PDUFA) is a law enacted by Congress that gives powers to the FDA.

Want to learn more or edit this definition?
Click here to read more!